|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gomaa AI and Waked I: Recent advances in
multidisciplinary management of hepatocellular carcinoma. World J
Hepatol. 7:673–687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xie B, Wang DH and Spechler SJ: Sorafenib
for treatment of hepatocellular carcinoma: A systematic review. Dig
Dis Sci. 57:1122–1129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Woo HY and Heo J: Sorafenib in liver
cancer. Expert Opin Pharmacother. 13:1059–1067. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang M, Xu ZG, Shi Z, Shao D, Li O, Li W,
Li ZJ, Wang KZ and Chen L: Inhibitory effect of celecoxib in lung
carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase
A2 and peroxisome proliferator-activated receptor gamma.
Mol Cell Biochem. 355:233–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dan P, Rosenblat G and Yedgar S:
Phospholipase A2 activities in skin physiology and
pathology. Eur J Pharmacol. 691:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lim SC, Cho H, Lee TB, et al: Impacts of
cytosolic phospholipase A2, 15-prostaglandin dehydrogenase and
cyclooxygenase-2 expressions on tumor progression in colorectal
cancer. Yonsei Med J. 51:692–699. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tosato G, Segarra M and Salvuccil O:
Cytosolic phospholipase A2{alpha} and cancer: A role in tumor
angiogenesis. J Natl Cancer Inst. 102:1377–1379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng Z, He X, Xie C, Hua S, Li J, Wang T,
Yao M, Vignarajan S, Teng Y, Hejazi L, et al: Targeting cytosolic
phospholipase A2 α in colorectal cancer cells inhibits
constitutively activated protein kinase B (AKT) and cell
proliferation. Oncotarget. 15:12304–12316. 2014.
|
|
10
|
Patel MI, Singh J, Niknami M, et al:
Cytosolic phospholipase A2-alpha: A potential therapeutic target
for prostate cancer. Clin Cancer Res. 14:8070–8079. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsubayashi H, Infante JR, Winter J, et
al: Tumor COX-2 expression and prognosis of patients with
resectable pancreatic cancer. Cancer Biol Ther. 6:1569–1575. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Singh B, Berry JA, Shoher A, Ramakrishnan
V and Lucci A: COX-2 overexpression increases motility and invasion
of breast cancer cells. Int J Oncol. 26:1393–1399. 2005.PubMed/NCBI
|
|
13
|
Chen C, Yu Z, Li Y, Fichna J and Storr M:
Effects of berberine in the gastrointestinal tract - a review of
actions and therapeutic implications. Am J Chin Med. 42:1053–1070.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Birdsall TC and Kelly GS: Berberine:
Therapeutic potential of an alkaloid found in several medicinal
plants. Altern Med Rev. 2:94–103. 1997.
|
|
15
|
Li J, Cao B, Liu X, et al: Berberine
suppresses androgen receptor signaling in prostate cancer. Mol
Cancer Ther. 10:1346–1356. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chidambara Murthy KN, Jayaprakasha GK and
Patil BS: The natural alkaloid berberine targets multiple pathways
to induce cell death in cultured human colon cancer cells. Eur J
Pharmacol. 688:14–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang M, Xu ZG, Shi Z, et al: Inhibitory
effect of celecoxib in lung carcinoma by regulation of
cyclooxygenase-2/cytosolic phospholipase A2 and peroxisome
proliferator-activated receptor gamma. Mol Cell Biochem.
355:233–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Good Laboratory Practice for Drugs. China
Food and Drug Administration; Beijing: 1999
|
|
19
|
Wang L, Liu L, Shi Y, et al: Berberine
induces caspase-independent cell death in colon tumor cells through
activation of apoptosis-inducing factor. PLoS One. 7:e364182012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuo HP, Chuang TC, Yeh MH, et al: Growth
suppression of HER2-overexpressing breast cancer cells by berberine
via modulation of the HER2/PI3K/Akt signaling pathway. J Agric Food
Chem. 59:8216–8224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patil JB, Kim J and Jayaprakasha GK:
Berberine induces apoptosis in breast cancer cells (MCF-7) through
mitochondrial-dependent pathway. Eur J Pharmacol. 645:70–78. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hwang JM, Kuo HC, Tseng TH, Liu JY and Chu
CY: Berberine induces apoptosis through a mitochondria/caspases
pathway in human hepatoma cells. Arch Toxicol. 80:62–73. 2006.
View Article : Google Scholar
|
|
23
|
Goldar S, Khaniani MS, Derakhshan SM and
Baradaran B: Molecular mechanisms of apoptosis and roles in cancer
development and treatment. Asian Pac J Cancer Prev. 16:2129–2144.
2015.PubMed/NCBI
|
|
24
|
Fabregat I, Roncero C and Fernández M:
Survival and apoptosis: A dysregulated balance in liver cancer.
Liver Int. 27:155–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Norberg E, Orrenius S and Zhivotovsky B:
Mitochondrial regulation of cell death: Processing of
apoptosis-inducing factor (AIF). Biochem Biophys Res Commun.
396:95–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Candé C, Vahsen N, Garrido C and Kroemer
G: Apoptosis-inducing factor (AIF): Caspase-independent after all.
Cell Death Differ. 11:591–595. 2004.PubMed/NCBI
|
|
27
|
Tan YL, Goh D and Ong ES: Investigation of
differentially expressed proteins due to the inhibitory effects of
berberine in human liver cancer cell line HepG2. Mol Biosyst.
2:250–258. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dan P, Rosenblat G and Yedgar S:
Phospholipase A2 activities in skin physiology and
pathology. Eur J Pharmacol. 691:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Singh T, Vaid M, Katiyar N, Sharma S and
Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma
cancer cell migration by reducing the expressions of
cyclooxygenase-2, prostaglandin E2 and prostaglandin
E2 receptors. Carcinogenesis. 32:86–92. 2011. View Article : Google Scholar
|
|
30
|
Ying Z, Tojo H, Komatsubara T, Nakagawa M,
Inada M, Kawata S, Matsuzawa Y and Okamoto M: Enhanced expression
of group II phospholipase A2 in human hepatocellular carcinoma.
Biochim Biophys Acta. 1226:201–205. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dymkowska D, Szczepanowska J, Wieckowski
MR and Wojtczak L: Short-term and long-term effects of fatty acids
in rat hepatoma AS-30D cells: The way to apoptosis. Biochim Biophys
Acta. 1763:152–163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Greenhough A, Smartt HJ, Moore AE, et al:
The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and
adaptation to the tumour microenvironment. Carcinogenesis.
30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
